Albumin ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 2 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02479802 (ClinicalTrials.gov) | November 2014 | 10/6/2015 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis | Pilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Albumin | Instituto Grifols, S.A. | NULL | Completed | 18 Years | 70 Years | All | 13 | Phase 2 | Spain |
| 2 | EUCTR2013-004842-40-ES (EUCTR) | 09/05/2014 | 07/03/2014 | Pilot study to evaluate the effect of plasma exchange with albumin in patients with amyotrophic lateral sclerosis | Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis - Albumin in ALS | Amytrophic Lateral Sclerosis (ALS) MedDRA version: 16.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Albutein 5% INN or Proposed INN: albúmina humana Other descriptive name: HUMAN ALBUMIN SOLUTION | Instituto Grifols S.A. | NULL | Not Recruiting | Female: yes Male: yes | Phase 4 | Spain |